<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33293">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01685619</url>
  </required_header>
  <id_info>
    <org_study_id>AML-MDS 01-2011</org_study_id>
    <nct_id>NCT01685619</nct_id>
  </id_info>
  <brief_title>AML-MDS Novel Prognostic Tests Clinical Study</brief_title>
  <official_title>A Multi-Centre Observational Prospective Cohort Study Involving the Collection of Clinical Information and Biological Specimens for the Evaluation of Novel Prognostic Tests for Myelodysplasia and Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stephen Couban</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Terry Fox Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Capital District Health Authority, Canada</source>
  <oversight_info>
    <authority>Canada:  Submission of this trial to Health Canada is not required.  (This has been confirmed with Health Canada.)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will provide the study specimens (samples of bone marrow and blood) and
      the clinical data for a pan-Canadian collaborative research project developed by the MDS/AML
      Research Consortium. The goal of this project involves the evaluation and potential
      validation of five novel prognostic tests for myelodysplasia (MDS) and/or acute myeloid
      leukemia (AML), as well as an analysis of health economic and socio-ethical implications
      related to the potential introduction of these tests into the clinical setting.  The
      over-arching goal is to improve the outcomes of patients with MDS and AML. The primary
      hypothesis is that one or more of the laboratory tests being evaluated in conjunction with
      this study, either alone or in combination with other laboratory tests (either established
      or under investigation in this project), will have statistically significant prognostic
      value either alone or in combination with established clinical risk factors.

      The clinical study will involve the enrollment of 200 adults with AML and 200 adults with
      MDS over a 2.5 year period.  Participants will be followed on study for two years.  Bone
      marrow and blood specimens will be collected at diagnosis and at other time points as
      required for the development of the five laboratory tests.

      Participants will be assigned to treatment according to local institutional practice and
      will be followed for up to 2 years.  Health economic and quality of life questionnaires will
      be administered at key time points.  Data will be collected regarding participant
      characteristics, diagnosis, disease features, treatment and clinical outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two of the tests involve a technology called flow cytometry.   Both of the flow cytometry
      tests are used to predict whether a person is likely to have a good response to chemotherapy
      or not.

      Three of the tests involve new genetic-based technology.  One of these tests is called
      comparative genomic profiling.  This test can detect genetic abnormalities that current
      testing methods are not able to detect.  Another test involves micro-RNA profiling.  The
      final test involves RNA sequencing. The researchers think these tests might be useful in
      predicting how well a person will respond to treatment.

      The novel laboratory tests being evaluated as part of this study are still in the early
      phases of development and cannot be used for clinical decision making. Participants enrolled
      in this study will not be informed regarding their individual results with respect to the
      study tests that are conducted using their biospecimens.

      The following information (data) will be collected regarding study participants: diagnosis,
      results of relevant clinical tests, age, gender, treatment and outcome during the 2 year
      study follow-up period. The study also involves the completion of study questionnaires at
      six different time points over the course of the two year study follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Prognostic capacity of the candidate tests (alone and in combination) to predict response to treatment, time to relapse, time to death.</measure>
    <time_frame>Two years following the completion of enrollment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>For the AML cohort, the candidate prognostic tests will be analyzed with adjustments for following clinical factors: age, white blood cell count at presentation, antecedent hematologic disorder, FLT-3 status, Karnofsky Performance Status (KPS), cytogenetic sub-group (using WHO 2008). For the MDS cohort the candidate prognostic tests will be analyzed with adjustments for following clinical factors: age, KPS, karyotype, bone marrow blast count and number of cytopenias at diagnosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost impact of candidate tests.</measure>
    <time_frame>Two years following the completion of enrollment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The cost-effectiveness of the candidate tests for AML and MDS treatment will be projected with the aid of economic simulation models.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Societal risks and benefits related to the candidate tests.</measure>
    <time_frame>Two years following the completion of enrollment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>A comparative analysis of policies and regulations in Canada governing prognostic tests will be undertaken (including tests that utilize RNA and DNA based technologies).  In addition, input will be obtained from key stakeholders.  This information will be used to develop a set of guidelines and best practices for this type of research.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>AML Cohort</arm_group_label>
    <description>This cohort is comprised of participants who have acute myelogenous leukemia (AML).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDS Cohort</arm_group_label>
    <description>This cohort is comprised of participants who have myelodysplastic syndrome (MDS).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Some of the laboratory tests that will be evaluated as part of this study will utilize RNA
      and/or DNA.  There may be biospecimens left over after the work related to this study is
      complete.  At the time of consent for the study, participants will be asked to provide
      consent (or decline their consent) regarding the use of leftover specimens (including RNA
      and DNA) for other research.  The details regarding this other research are provided in the
      protocol and consent template.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Prospective participants will include patients with known or supsected AML or MDS who are
        being treated and/or assessed at a participating site.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        There are two parts to the study:  Part One (Collection of Biospecimens) and Part Two (Two
        year follow-up that includes data collection regarding treatment, outcome and
        questionnaire completion).

        INCLUSION CRITERIA (PART ONE):

        Prospective participants can be included in the study if:

          -  The participant is 18 years of age or older

          -  The participant is suspected to have a new diagnosis of MDS (including CMML) , OR
             suspected to have a new diagnosis of AML  excluding acute promyelocytic leukemia
             (APL), OR known to have a diagnosis of MDS (including CMML) confirmed by bone marrow
             aspirate and biopsy no more than one year prior to the date of enrollment AND without
             commencement of definitive therapy prior to enrollment

          -  The participant is scheduled to have a diagnostic or confirmatory bone marrow
             aspirate and biopsy at a participating site,  or in the case of prospective
             participants with an established diagnosis of MDS (including CMML), must be able to
             undergo a bone marrow aspirate for the study at the participating site

          -  The participant must be able to read and/or understand spoken English or French so
             that they will be eligible for Part Two of the study

          -  The participant must be able to understand and sign the informed consent form
             applicable to their situation

        EXCLUSION CRITERIA (PART ONE):

        Prospective participants should be excluded from the study if:

          -  The participant has already received definitive therapy for AML or MDS

          -  The participant has a diagnosis of MDS that was confirmed more than one year prior to
             the date of enrollment

        INCLUSION CRITERIA (PART TWO):

        Participants who have been enrolled in Part One will be eligible to participate in the
        full two year study follow-up component if they meet the following criteria:

          -  Confirmed diagnosis of either MDS, CMML or AML  (excluding APL)

          -  Sufficient cell count for the MDS/AML Clinical Study requirements as follows:

        For participants with suspected (or known) AML:

        The blast count of the peripheral blood taken at diagnosis must be greater than 1 x10^6
        blast count/mL

          -  It must be possible to earmark for the MDS/AML Study:

          -  3 vials 1.0 x 10^7/mL mononuclear peripheral blood cells

          -  1 vial 0.5 x 10^7/mL mononuclear bone marrow cells

        Cells are to be prepared according to the site's local cell bank procedures so that they
        can be stored and transported to study labs as needed.

        At sites participating in the Hogge Assay:

        In addition to the specimens described above, it must be possible to provide 2 mL of fresh
        bone marrow or 5 mL of fresh peripheral blood with &gt; 1 x 10^6 blast count/mL

        For participants with suspected (or known) MDS:

          -  It must be possible to earmark for the MDS/AML Study:

          -  2 vials 1.0 x 10^7/mL mononuclear peripheral blood cells

          -  2 vials 1.0 x 10^7/mL mononuclear bone marrow cells

        Cells are to be prepared according to the site's local cell bank procedures so that they
        can be stored and transported to study labs as needed.

        EXCLUSION CRITERIA (PART TWO):

        Participants who have been enrolled in Part One will not be eligible to participate in the
        full two year study follow-up component if they:

          -  Do not have sufficient cell count for the MDS/AML Clinical Study requirements as set
             out in Section 11.3

          -  It is confirmed after enrollment that they do not have a diagnosis of MDS, CMML or
             AML

          -  A diagnosis of APL is confirmed
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Couban, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Capital District Health Authority, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen Couban, M.D.</last_name>
    <phone>902-473-8562</phone>
    <email>Stephen.Couban@cdha.nshealth.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Holly Kerr, B.A.</last_name>
    <phone>604-875-4111</phone>
    <phone_ext>63196</phone_ext>
    <email>hkerr@bccancer.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lynn Savoie, M.D.</last_name>
      <phone>403-944-1880</phone>
      <email>Lynn.Savoie@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Lynn Savoie, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Hogge, M.D., Ph.D.</last_name>
      <phone>604-875-4863</phone>
      <email>dhogge@bccancer.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Holly Kerr, B.A.</last_name>
      <phone>604-875-4111</phone>
      <phone_ext>63196</phone_ext>
      <email>hkerr@bccancer.bc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Donna Hogge, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Seftel, M.D.</last_name>
      <phone>204-787-2108</phone>
      <email>Matthew.Seftel@cancercare.mb.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kathryn Dyck, B.A.</last_name>
      <phone>204-787-2127</phone>
      <email>Kathryn.Dyck@cancercare.mb.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Seftel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Couban, M.D.</last_name>
      <phone>902-473-8562</phone>
      <email>Stephen.Couban@cdha.nshealth.ca</email>
    </contact>
    <contact_backup>
      <last_name>Susan Pleasance, BScN</last_name>
      <phone>902-473-7585</phone>
      <email>Susan.Pleasance@cdha.nshealth.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Couban, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre (formerly Princess Margaret Hospital)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Minden, M.D.</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>5106</phone_ext>
      <email>Mark.Minden@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Arruda, M.Sc.</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>2648</phone_ext>
      <email>andrea.arruda@uhnresearch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Minden, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Bergeron, M.D.</last_name>
      <phone>514-252-3404</phone>
      <email>juliebergeron.hmr@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Julie Lu, B.Sc.</last_name>
      <phone>514-254-7455</phone>
      <phone_ext>3336</phone_ext>
      <email>jtlu.hmr@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Julie Bergeron, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 4, 2013</lastchanged_date>
  <firstreceived_date>September 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Capital District Health Authority, Canada</investigator_affiliation>
    <investigator_full_name>Stephen Couban</investigator_full_name>
    <investigator_title>Interim Head, Division of Hematology, Director, Blood and Marrow Transplant Program</investigator_title>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>MDS</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Prognostic</keyword>
  <keyword>Economic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
